412 related articles for article (PubMed ID: 31128914)
1. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H.
Parween S; DiNardo G; Baj F; Zhang C; Gilardi G; Pandey AV
J Steroid Biochem Mol Biol; 2020 Feb; 196():105507. PubMed ID: 31669572
[TBL] [Abstract][Full Text] [Related]
3. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
4. Variability in Loss of Multiple Enzyme Activities Due to the Human Genetic Variation P284T Located in the Flexible Hinge Region of NADPH Cytochrome P450 Oxidoreductase.
Parween S; Rojas Velazquez MN; Udhane SS; Kagawa N; Pandey AV
Front Pharmacol; 2019; 10():1187. PubMed ID: 31749697
[TBL] [Abstract][Full Text] [Related]
5. Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase.
Udhane SS; Parween S; Kagawa N; Pandey AV
Front Pharmacol; 2017; 8():580. PubMed ID: 28970799
[TBL] [Abstract][Full Text] [Related]
6. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
Subramanian M; Agrawal V; Sandee D; Tam HK; Miller WL; Tracy TS
Pharmacogenet Genomics; 2012 Aug; 22(8):590-7. PubMed ID: 22547083
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques.
Uno Y; Uehara S; Murayama N; Yamazaki H
Chem Res Toxicol; 2018 Dec; 31(12):1373-1381. PubMed ID: 30412386
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.
Agrawal V; Huang N; Miller WL
Pharmacogenet Genomics; 2008 Jul; 18(7):569-76. PubMed ID: 18551037
[TBL] [Abstract][Full Text] [Related]
9. Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase.
Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):64-70. PubMed ID: 27032764
[TBL] [Abstract][Full Text] [Related]
10. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
[TBL] [Abstract][Full Text] [Related]
11. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Tomalik-Scharte D; Maiter D; Kirchheiner J; Ivison HE; Fuhr U; Arlt W
Eur J Endocrinol; 2010 Dec; 163(6):919-24. PubMed ID: 20844025
[TBL] [Abstract][Full Text] [Related]
12. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.
Flück CE; Mullis PE; Pandey AV
Biochem Biophys Res Commun; 2010 Oct; 401(1):149-53. PubMed ID: 20849814
[TBL] [Abstract][Full Text] [Related]
13. Exploring Novel Variants of the Cytochrome P450 Reductase Gene (
Rojas Velazquez MN; Therkelsen S; Pandey AV
Biomolecules; 2023 Nov; 13(12):. PubMed ID: 38136599
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population.
Krasniqi V; Dimovski A; Bytyqi HQ; Eftimov A; Šimičević L; Božina N
Arh Hig Rada Toksikol; 2017 Sep; 68(3):180-184. PubMed ID: 28976882
[TBL] [Abstract][Full Text] [Related]
15. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
[TBL] [Abstract][Full Text] [Related]
16. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.
Ota T; Kamada Y; Hayashida M; Iwao-Koizumi K; Murata S; Kinoshita K
Int J Med Sci; 2015; 12(1):78-82. PubMed ID: 25552922
[TBL] [Abstract][Full Text] [Related]
17. Development of Caco-2 cells expressing four CYPs via a mammalian artificial chromosome.
Ohta Y; Kazuki K; Abe S; Oshimura M; Kobayashi K; Kazuki Y
BMC Biotechnol; 2020 Aug; 20(1):44. PubMed ID: 32819341
[TBL] [Abstract][Full Text] [Related]
18. Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances.
Hosaka S; Murayama N; Satsukawa M; Uehara S; Shimizu M; Iwasaki K; Iwano S; Uno Y; Yamazaki H
Biopharm Drug Dispos; 2015 Dec; 36(9):636-43. PubMed ID: 26348733
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
20. Contribution of the human cytochrome P450 2C subfamily to the metabolism of and the interactions with endogenous compounds including steroid hormones.
Niwa T; Yasuda S; Yamamoto Y; Murakami M; Ishii R
Pharmazie; 2021 Dec; 76(12):611-613. PubMed ID: 34986958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]